ExeVir

ExeVir Bio is a biotechnology startup based in Belgium, established in 2020. The company's slogan "Rapid Viral control in a world that needs it" reflects its core focus on leveraging Llama-derived antibody (VHH) technology to develop robust antiviral therapies providing broad protection against coronaviruses. Their lead compound, an enhanced variant of VHH72-Fc, has showcased binding capabilities to a conserved epitope in SARS-CoV-1 and SARS-CoV-2 viruses, hindering their cell entry. This breakthrough approach holds promise for both therapeutic and prophylactic use, potentially slowing viral replication, reducing inflammation, and offering support to those at increased risk of severe illness from Covid-19. Recently, ExeVir Bio secured a €1.60M grant investment on 28 June 2023 from Agentschap Innoveren & Ondernemen, showcasing investor confidence in their innovative viral control solutions. With a clear focus on addressing global health challenges, particularly in the context of the ongoing pandemic, ExeVir Bio's commitment to leveraging cutting-edge biotechnology for impactful solutions in viral control positions it as a compelling prospect for venture capital investment. As the demand for advanced antiviral therapies continues to escalate, ExeVir Bio's innovative approach and recent investment raise indicate a promising trajectory for the company's growth and potential impact in the biotechnology and healthcare industries.